alligator bioscience - Robuta Search

https://www.accessnewswire.com/newsroom/en/biotechnology/nomination-committee-appointed-in-respect-of-agm-2025-in-alligator-bioscience-ab-937365 Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB LUND, SE / ACCESSWIRE / October 31, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden, October 31, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX)... nomination committee agm 2025 alligator bioscience appointed respect https://www.news-medical.net/news/20260411/Alligator-Bioscience-provides-an-update-on-mitazalimab.aspx Alligator Bioscience provides an update on mitazalimab Apr 11, 2026 - Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding... alligator bioscience an update provides https://www.prnewswire.co.uk/news-releases/alligator-bioscience-announces-immuno-oncology-research-collaboration-and-license-agreement-with-orion-corporation-820389393.html Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with... /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license... alligator bioscience immuno oncology research collaboration license agreement announces https://www.accessnewswire.com/newsroom/en/biotechnology/invitation-to-alligator-biosciences-earnings-call-on-12-february-2026-1133903 Invitation to Alligator Bioscience's Earnings Call on 12 February 2026 LUND, SE / ACCESS Newswire / February 5, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing... alligator bioscience earnings call on 12 invitation https://www.biospace.com/alligator-bioscience-ab-appoints-chief-operating-officer Alligator Bioscience AB Appoints Chief Operating Officer - BioSpace Dec 2, 2019 - Alligator Bioscience announced that the company has appointed Dr Malin Carlsson as Chief Operating Officer. chief operating officer alligator bioscience ab appoints https://www.home.saxo/nb-no/markets/stocks/atorx-xome Alligator Bioscience AB aksje | Saxo Bank Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. alligator bioscience ab aksje saxo bank https://www.prnewswire.com/news-releases/alligator-bioscience-ab-interim-report-januarymarch-2021-301277465.html Alligator Bioscience AB: Interim report January-March 2021 /PRNewswire/ -- High activity during the first quarter "So far, 2021 has been characterized by high activity, with a research collaboration that validates... alligator bioscience interim report ab january march https://www.prnewswire.co.uk/news-releases/alligator-bioscience-announces-new-senior-director-of-communications-amp-investor-relations-859137320.html Alligator Bioscience Announces New Senior Director of Communications & Investor Relations /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Julie Silber has joined the company as the new Senior Director of... director of communications alligator bioscience announces new senior https://www.home.saxo/cs-cz/markets/stocks/atorx-xome Alligator Bioscience AB akcie | Saxo Bank Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. alligator bioscience ab akcie saxo bank https://www.prnewswire.com/news-releases/alligator-bioscience-announces-completion-of-600-mg-dose-cohort-for-ator-1017-dose-escalation-and-enrollment-for-900-mg-dose-cohort-commences-301515562.html Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and... /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from...